September 28, 2018 10:00 AM EDTUpdated 10:15 AM
Peer Review

Fred Aslan re­turns to biotech as pres­i­dent of Vi­vid­ion; Zai Lab scoops Por­to­la's Tao Fu to spear­head US op­er­a­tions

Amber Tong

→ Af­ter a stint as CEO of a med­ical de­vice com­pa­ny, Re­cep­tos co-founder and Ven­rock alum Fred Aslan is back in the drug de­vel­op­ment busi­ness …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times